AstraZeneca posted a 67% fall in first-quarter profit, below analysts' expectations, as sales of its best-selling drugs continued to be dented by generic competition.
via WSJ.com: US Business http://ift.tt/1mH0zfg
via WSJ.com: US Business http://ift.tt/1mH0zfg
Nessun commento:
Posta un commento